Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 10163Neoplasms 7801Carcinoma, Non-Small-Cell Lung 5744Prostatic Neoplasms 5016Colorectal Neoplasms 4588Lung Neoplasms 3716Leukemia, Myeloid, Acute 3097Neoplasm Metastasis 3074Multiple Myeloma 3073Pancreatic Neoplasms 2837Melanoma 2646Lymphoma 2569Ovarian Neoplasms 2565Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Recurrence 2221Head and Neck Neoplasms 2095Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia 2011Brain Neoplasms 1899Glioblastoma 1791Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1714Uterine Cervical Neoplasms 1684Lymphoma, Follicular 1651Squamous Cell Carcinoma of Head and Neck 1649Lymphoma, Large B-Cell, Diffuse 1596Carcinoma, Renal Cell 1574

Interventions

icotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × EGF-R Positive Non-Small Cell Lung Cancer × Clear all
NCT06287593 2024-04-24

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

Zhejiang University

Phase NA Not yet recruiting
300 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03749213 2018-11-21

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage â…¢A-N2 Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
36 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03349203 2018-07-18

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
60 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡